{"id":"NCT04442490","sponsor":"Biogen","briefTitle":"A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)","officialTitle":"A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-05-12","primaryCompletion":"2021-03-26","completion":"2021-04-21","firstPosted":"2020-06-22","resultsPosted":"2023-12-05","lastUpdate":"2023-12-22"},"enrollment":543,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"SAGE-217","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"SAGE-217 50 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study to evaluate the efficacy of SAGE-217 in the treatment of participants with MDD.","primaryOutcome":{"measure":"Change From Baseline in the 17-item HAM-D Total Score at Day 15","timeFrame":"Baseline, Day 15","effectByArm":[{"arm":"Placebo","deltaMin":-12.3,"sd":0.5},{"arm":"SAGE-217 50 mg","deltaMin":-14.1,"sd":0.51}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0141"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":39,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":269},"commonTop":["Headache","Somnolence","Dizziness","Nausea","Diarrhoea"]}}